Avonex(interferon beta-1a)
Avonex, Rebif (interferon beta-1a) is a protein pharmaceutical. Interferon beta-1a was first approved as Avonex on 1996-05-17. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Avonex, Rebif
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avonex avonex pen | Biologic Licensing Application | 2020-12-16 |
| rebif rebif rebidose | Biologic Licensing Application | 2020-10-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple sclerosis | EFO_0003885 | D009103 | G35 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
interferon beta-1a, Avonex, Biogen Inc. | |||
| 2103-05-17 | Orphan excl. | ||
Patent Expiration
No data
Clinical
Clinical Trials
149 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | 3 | 6 | 21 | 18 | 11 | 58 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 5 | 8 | 14 | 12 | 18 | 56 |
| Covid-19 | D000086382 | U07.1 | — | 3 | 4 | 2 | 2 | 10 | |
| Optic neuritis | D009902 | EFO_0007405 | H46 | — | — | — | 2 | — | 2 |
| Transverse myelitis | D009188 | G37.3 | — | — | — | 1 | — | 1 | |
| Neuritis | D009443 | — | — | — | 1 | — | 1 | ||
| Demyelinating diseases | D003711 | — | — | — | 1 | — | 1 | ||
| Myelitis | D009187 | G04.91 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sars-cov-2 | D000086402 | — | 1 | 1 | — | — | 2 | ||
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 1 | — | — | 1 |
| Coronavirus | D017934 | — | 1 | 1 | — | — | 1 | ||
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | — | 1 |
| Hepatitis c | D006526 | B19.2 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | — | 2 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 2 | — | — | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
| Multiple organ failure | D009102 | EFO_1001373 | — | 1 | — | — | — | 1 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 1 | — | — | — | 1 |
| Chronic inflammatory demyelinating polyradiculoneuropathy | D020277 | EFO_1000868 | G61.81 | — | 1 | — | — | — | 1 |
| Spinal cord diseases | D013118 | HP_0002196 | G95.9 | — | 1 | — | — | — | 1 |
| Tropical spastic paraparesis | D015493 | EFO_0007527 | G04.1 | — | 1 | — | — | — | 1 |
| Htlv-i infections | D015490 | EFO_0007316 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 8 | — | — | — | — | 8 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 | ||
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | 1 | 1 | |
| Prenatal exposure delayed effects | D011297 | — | — | — | — | 1 | 1 | ||
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | INTERFERON BETA-1A |
| INN | — |
| Description | Interferon beta precursor (IFN-beta) (Fibroblast interferon) |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 145258-61-3 |
| RxCUI | 75917 |
| ChEMBL ID | CHEMBL1201562 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00060 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Avonex - Biogen
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,403 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
211,773 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more